期刊文献+

趋化因子受体CXCR7在卵巢上皮性癌中的表达及其临床意义 被引量:2

Expression and clinical significance of chemokine receptor CXCR7 in epithelial ovarian carcinoma
下载PDF
导出
摘要 目的探讨趋化因子受体CXCR7在卵巢上皮性癌(卵巢癌)组织中的表达情况及其临床意义。方法采用免疫组化方法检测57例卵巢癌组织、15例良性卵巢肿瘤组织及15例正常卵巢生发上皮组织中CXCR7蛋白的阳性表达,并通过χ2检验、Kaplan-Meier法及多因素Cox回归分析等方法探讨CXCR7蛋白的阳性表达与卵巢癌患者临床病理特征及预后的相关性。结果卵巢癌组织中CXCR7蛋白的阳性表达率为68.42%(39/57),良性卵巢肿瘤组织中CXCR7蛋白的阳性表达率为26.67%(4/15),正常卵巢生发上皮组织中CXCR7蛋白的阳性表达率为13.33%(2/15),3组间差异有统计学意义(χ2=19.97,P=0.000 1)。CXCR7蛋白的阳性表达与患者的年龄、术前CA125水平、卵巢癌肿瘤病理类型、残余肿瘤直径、腹水的含量及肿瘤的大小无关(P>0.05),而与患者FIGO分期、肿瘤的组织学分级、有无淋巴结转移及腹腔转移有关(P<0.05)。单因素及多因素分析发现,CXCR7蛋白表达水平、患者FIGO分期、肿瘤的组织学分级、有无淋巴结转移及腹腔转移与卵巢癌患者的总生存率和无瘤生存率存在统计学意义上的关联。Kaplan-Meier曲线显示,卵巢癌患者中CXCR7蛋白阳性患者的总生存率和无瘤生存率均较CXCR7蛋白阴性患者降低,差异有统计学意义(P<0.05)。结论卵巢癌患者组织中CXCR7蛋白的表达升高,且与转移复发及预后存在密切联系,提示CXCR7可能是预测卵巢癌预后及治疗的一项重要指标。 Objective To investigate the expression and clinical significance of chemokine receptor CXCR7 in epithelial ovarian carcinoma(EOC)tissues.Methods Immunohistochemical technique was used to detect the protein expression of CXCR7 in 57EOC tissues,15 benign ovarian tumor tissues and 15 normal ovarian germinal epithelium tissues.The chi-square test,Kaplan-Meier method and multivariate Cox regression analysis were used to evaluate the relationship between the expression of CXCR7 and clinicopathological features and its prognosis.Results The positive expression rates of CXCR7 in EOC tissue,benign ovarian tumor tissue and normal ovarian germinal epithelium tissue were 68.42%(39/57),26.67%(4/15)and 13.33%(2/15),respectively(χ2=19.97,P=0.000 1).The positive expression of CXCR7 was significantly correlated with the International Federation of Gynecology and Obstetrics(FIGO)stages,histological grade,lymph node metastasis and peritoneal metastasis(P<0.05),but not with age,preoperative CA125 level,histological type of EOC,residual tumor diameter,ascites content,or tumor size(P>0.05).Univariate analysis and multivariate analysis results showed that the positive expression of CXCR7,FIGO stage,histological grade,lymph node metastasis and peritoneal metastasis were statistically correlated with the overall survival and disease-free survival of EOC patients.Kaplan-Meier curve revealed that both overall survival and disease-free survival in EOC patients with positive expression of CXCR7 were significantly lower than those in EOC patients with negative CXCR7(P<0.05).Conclusion The high expression of CXCR7 is closely related to the recurrence and metastasis in EOC patients,which indicates that CXCR7 might be a potential predictor and an important therapeutic indicator of EOC.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2016年第5期552-556,共5页 Academic Journal of Second Military Medical University
关键词 卵巢肿瘤 CXCR7受体 复发 肿瘤转移 预后 ovarian neoplasms CXCR7receptors recurrence neoplasm metastasis prognosis
  • 相关文献

参考文献7

二级参考文献185

  • 1Huang, Fan,Geng, Xiao-Ping.Chemokines and hepatocellular carcinoma[J].World Journal of Gastroenterology,2010,16(15):1832-1836. 被引量:20
  • 2杨秀利,储以微,乔滨,熊思东.ITAC转染乳腺癌细胞系4T1的体内外生物学行为研究[J].中国癌症杂志,2005,15(3):252-256. 被引量:1
  • 3蒋玉萍,吴小华,吴文新,尹桂然.CXCL12及受体CXCR4在卵巢上皮性癌中的表达及其临床意义[J].肿瘤,2006,26(9):851-855. 被引量:4
  • 4Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta- analysis. J Clin Oncol 2002;20:1248-59.
  • 5Gallo A, Frigerio L. Neoadjuvant chemotherapy and surgical considerations in ovarian cancer. Curr Opin Obstet Gynecol 2003;15:25-31.
  • 6McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer. N Engl J Med 1996;334:1-6.
  • 7Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage ⅢC ovarian carcinoma. Cancer 2001;92:2585-91.
  • 8Morice P, Dubernard G, Rey A, et al. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coil Surg 2003;197:955-63.
  • 9Vergote I, De Wever I, Tjalma W, et al. Neoadjuvant chemotherapy or primary debulldng surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients Gynecol Oncol 1998;71:431-6.
  • 10Loizzi V, Cormio G, Resta L, et al. Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. IntJ Gynecol Cancer 2005;15:217-23.

共引文献66

同被引文献26

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部